Reed Smith's Life Sciences Health Industry Group is hosting a Life Sciences CLE Day at our Philadelphia office on Thursday, November 10. The day starts with breakfast and networking at 8:30 a.m. and sessions commence at 9 a.m. The event, which includes a working lunch, concludes at 2:30 p.m. This program is geared toward in-house counsel; space is limited.
Sessions include:
- "Major Drug and Device Decisions of 2016" presented by Eric Alexander and Kelly Hibbert
- "FCA Post-Escobar: Materiality Matters" presented by Thomas Suddath, Brian Himmel, and Lindsey Harteis
- "Purple is the New Orange: A Primer on the Biologics-Biosimilars Landscape," presented by Lisa Chiarini and Rudolf Hutz
- "Looking for Law in All the Wrong Places: Perspectives on the Best (and Worst) Product Liability Jurisdictions," presented by Rick Fuentes Ph.D., Barbara Binis, Melissa Geist, and Marilyn Moberg
- "Regulating Healthcare on a New Wavelength: The FCC's Role In Wireless Medical Devices," presented by Paul Bond and Samuel Cullari
- "Implied Preemption – It's Not Just for Generic Drugs Anymore (Plus Off-Label Promotions Update)," presented by James Beck and Rachel Weil
The CLE Day is presumptively approved for 6 CLE credits in New Jersey and 5 CLE credits in Pennsylvania. An application for Delaware credit is pending. For lawyers licensed in New York, this course is eligible for 6 credits under New York's Approved Jurisdiction Policy. We hope to see you there!
For more information, or to register, please visit our website.
This article is presented for informational purposes only and is not intended to constitute legal advice.
